France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a revenue growth strategy in oncology and neurology. The deal brings an Edgewise drug in clinical development for two rare neuromuscular disorders with limited treatment options.
The post Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics appeared first on MedCity News.
Providence Study Finds Scale Unlocks the Value of Ambient AI-Assisted Clinician Documentation
Ambient AI is often pitched as a way to see more patients. The real return at Providence looked different across 1,500-plus clinicians, and the timeline
